Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $5.12.

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Craig Hallum initiated coverage on Fractyl Health in a research report on Wednesday. They set a “buy” rating and a $4.00 price objective on the stock. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th.

Insider Buying and Selling

In related news, Director Ian Sheffield bought 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the purchase, the director owned 35,000 shares in the company, valued at approximately $25,550. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Bradley purchased 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the purchase, the director owned 84,622 shares in the company, valued at approximately $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 171,493 shares of company stock worth $127,150. 8.52% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GUTS. Nantahala Capital Management LLC bought a new stake in shares of Fractyl Health during the 3rd quarter valued at about $19,298,000. Alyeska Investment Group L.P. bought a new position in shares of Fractyl Health in the 3rd quarter worth approximately $8,981,000. Rosalind Advisors Inc. purchased a new position in shares of Fractyl Health in the third quarter worth approximately $7,950,000. Woodline Partners LP boosted its holdings in shares of Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after buying an additional 4,908,693 shares during the last quarter. Finally, General Catalyst Group Management LLC bought a new stake in Fractyl Health during the second quarter valued at approximately $7,912,000.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.76 on Friday. The company’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.96. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.44. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market cap of $120.89 million, a price-to-earnings ratio of -0.59 and a beta of 2.29.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. On average, equities research analysts forecast that Fractyl Health will post -0.6 earnings per share for the current fiscal year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.